Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July

NEKTAR THERAPEUTICS

2026-Q1 EPS reported -$1.82 revenue$10,861,000

Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.
Cash & investments $731.6M; excludes $351M net proceeds from April offering.
R&D $35.7M, G&A $13.4M; total operating costs $49.9M.
Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026.
Closed public offerings raising $460M in Feb and $373.8M in April.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2026 results: revenue 10.9 million, net income 44.9 million, EPS 1.82.

Period: first quarter ended March 31, 2026
Revenue: 10.9 million
Net income: 44.9 million
EPS: 1.82
Result: reported results

Exact text from the filing

Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-26-053369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.